Recent, closed consultation topics are provided for information.
| Date closed |
Consultation topic |
|
4 July 2025 |
Proposed updates to the Guideline on the Regulation of Therapeutic Products in New Zealand: Bioequivalence of medicines
|
| 11 February 2025 |
Proposal to
change the regulatory and funding restrictions for stimulant
treatments for ADHD
|
| 27 October 2024 |
Proposed
updates to the Guideline on the Regulation of Therapeutic
Products in New Zealand: Clinical Trials - Citizen Space |
| 14 December 2023 |
Proposed updates to the
Guideline on the Regulation of Therapeutic Products in New Zealand: Pharmacovigilance -
New Zealand Ministry of Health - Citizen Space
|
| 6 October 2023 |
Clozapine Survey 2023 - New Zealand Ministry of Health - Citizen Space
|
| 23 September 2022 |
Proposed warning and advisory statement for ocular decongestants
used for eye redness and/or minor eye irritation
|
| 4 April 2022 |
Proposed warning and advisory statement relating to the harm of opioid abuse, misuse, and dependence |
| 8 November 2021 |
Proposed warning and advisory statements relating to the harm of long-term
use and overuse of stimulant laxatives |
| 8 April 2021 |
Review of Fees payable under the Medicines Act 1981 |
| 22 March 2021 |
Consultation on Plan to update the New Zealand Code of Good
Manufacturing Practice |
| 30 April 2020 |
Consultation on Contraceptive Standards |
|
31 January 2020 |
Consultation on proposed changes to current warning and advisory statements for paracetamol |
|
07 August 2019 |
Medicinal Cannabis Scheme Consultation |
|
08 August 2019 |
Proposed warning statements for substances (eg, allergens) in
medicines that may cause undesirable reactions |
|
08 August 2019 |
Changes to the prescribing restrictions for riluzole |
| 18 April 2019 |
Therapeutic Products Regulatory Scheme consultation |
| 7 December 2018 |
Proposed warning statement regarding a fire hazard on the labels
of paraffin-based skin products |
| 3 August 2018 |
Update to the Guideline on the Regulation of Therapeutic Products
- Part 11: Clinical Trials |
| 31 May 2018 |
Consultation
on the revision of CMN Form B |
| 27 April 2018 |
Review of fees payable under
the Medicines Regulations 1984
|
| 15 January 2018 |
Updating the guidance document 'How to change the legal classification
of a medicine in New Zealand |
| 15 January 2018 |
Observers at Ministerial Advisory Committee meetings
|
| 29 September 2017 |
Changes to the Label Statements Database for sedating antihistamines
available without prescription |
| 15 September 2017 |
Proposed change
to warning statements on labels of oral non-steroidal anti-inflammatory
drugs (NSAIDs) available without a prescription |
| 13 April 2017 |
Addition of warning statements on labels of topical miconazole
containing medicines available without prescription |
| 11 November 2016 |
Change to warning statements on labels of OTC loratadine and
desloratadine medicines |
| 31 March 2016 |
Consultation on Changes
to the Data sheet format, process and the Data sheet guideline |
| 22 June 2015 |
Addition
of warning statements on labels of OTC oral and topical diclofenac
medicines |
| 13 May 2015 |
Guideline on the
Regulation of Therapeutic Products in New Zealand. Part 8: Pharmacovigilance |
| 27 February 2015 |
New Zealand Medicines and Medical
Devices Recall Code |
| 9 January 2015 |
Proposed amendment to the Medicine Regulations 1984 re fluoride
in drinking water |
| 21 March 2014 |
Ministry of Health consultation on Psychoactive Substances Regulations |
| 3 March 2014 |
Removal
of warning statements from Label Statements Database for loratadine
and cetirizine |
| 3 March 2014 |
Changes
to the Label Statements Database for codeine-containing medicines |
| 3 March 2014 |
Changes
to the Label Statements Database for aspirin |
| 3 March 2014 |
Changes
to the prescribing restrictions for clozapine |
| 28 February 2014 |
Proposed
revision of abbreviated process policy |
| 18 October 2013 |
Consultation on the classification
of peptide-based performance and image enhancing drugs |
| 27 September 2013 |
Standards for Contraceptive
Devices supplied in New Zealand |
| 10 July 2013 |
Common Regulatory Framework Harmonisation
Proposal: International Harmonisation of Ingredient Names |
| 14 June 2013 |
Classification of
peptide-based performance and image enhancing drugs |
| 7 April 2013 |
Trans-Tasman
Early Warning System of Safety Concerns with Medicines and Medical
Devices |
| 28 February 2013 |
Medsafe signals planned changes to packaging requirements for
antidepressants |
| 21 February 2013 |
Description
of a possible joint regulatory scheme for therapeutic products
under ANZTPA |
| 31 January 2013 |
Planned
changes to GMP evidence required for active pharmaceutical ingredients
|
| 7 November 2012 |
Over-the-Counter
(OTC) Medicines Business Process Reform Consultation Paper |
| 25 May 2012 |
Proposed Business
Rule for Publication of Data Sheets |
| 27 August 2010 |
Uniform Recall
Procedure for Medicines and Medical Devices (the Recall code) |
| 26 March 2010 |
Proposal to
widen prescriber access to clozapine |
| 30 November 2009 |
Proposed
updates to the New Zealand Good Clinical Research Practice Guideline
|
| 20 November 2009 |
Submission
and publication processes for data sheets and Consumer Medicine
Information on the Medsafe website |
| 29 May 2009 |
Review
of Administrative Processes Associated with the Evaluation and
Classification of Medicines |
| 22 May 2009 |
Proposed
changes to fees payable under the Medicines Regulations 1984
(PDF document, 83 KB, 9 pages)
Medsafe Report
(PDF document, 108 KB, 15 pages)
Deloitte Report.pdf
(PDF document, 112 KB, 28 pages) |
| 15 May 2009 |
Proposed
update to the New Zealand Code of Good Manufacturing Practice |
